Autoimmune manifestations in human myelodysplasia: A positive correlation with interferon regulatory factor-1 (IRF-1) expression

Annals of the Rheumatic Diseases

Volumn 63, Issue 5, 2004, Pages 578-582

  Giannouli, S ^a   Tzoanopoulos, D ^b   Ritis, K ^b   Kartalis, G ^b   Moutsopoulos, H M ^a   Voulgarelis, M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON REGULATORY FACTOR 1; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; MONONUCLEAR CELL; MYELODYSPLASIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULITIS;

AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; DNA-BINDING PROTEINS; FEMALE; HUMANS; INTERFERON REGULATORY FACTOR-1; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER;

EID: 1942532187     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.012948     Document Type: Article

References (14)

1. Homblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996;33:150-62.
2. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 1988;54:903-13.
3. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994;77:829-39.
4. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993;259:968-71.
5. Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, et al. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 1994;9:3313-20.
6. Salkowski CA, Kopydlowski K, Blanco J, Cody MJ, McNally R, Vogel SN. IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice. J Immunol 1999;163:1529-36.
7. Ogasawara K, Hida S, Azimi N, Tagaya Y, Sato T, Yokochi-Fukuda T, et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998;391:700-3.
8. Kroger A, Koster M, Schroeder K, Hauser H, Mueller PP. Activities of IRF-1. J Interferon Cytokine Res 2002;22:5-14.
9. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
11. Tzoanopoulos D, Speletas M, Arvanitidis K, Veiopoulou C, Kyriaki S, Thyphronitis G, et al. Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia. Br J Haematol 2002;119:46-53.
12. Maruyama M, Fujita T, Taniguchi T. Sequence of a cDNA coding for human IRF-1. Nucleic Acids Res 1989;17:3292.
13. Bloch DA, Michel BA, Hunder GG, McShane DJ, Arend WP, Calabrese LH, et al. The American college of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum 1990;33:1068-73.
14. Tada Y, Ho A, Matsuyama T, Mak TW. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J Exp Med 1997;185:231-8.